%0 Journal Article %J Pharmacognosy Research %D 2013 %T Anti-diabetic Properties of Flavonoid Compounds Isolated from Hyphaene Thebaica Epicarp on Alloxan Induced Diabetic Rats %A Josline Y Salib %A Helana N Michael %A Emad Fawzy Eskande %K Anti-diabetic activity %K Epicarp %K Hyphaene Thebaica %K Novel Flavonoids %X

Background: Diabetes mellitus, becoming the third killer of mankind after cancer and cardiovascular diseases, is one of the most challenging diseases facing health care professionals today. That is why; there has been a growing interest in the therapeutic use of natural products for diabetes, especially those derived from plants. Aim: To evaluate the anti-diabetic activity together with the accompanying biological effects of the fractions and the new natural compounds of Hyphaene thebaica (HT) epicarp. Materials and Methods: 500 g of coarsely powdered of (HT) fruits epicarp were extracted by acetone. The acetone crude extract was fractionated with methanol and ethyl acetate leaving a residual water-soluble fraction WF . The anti-diabetic effects of the WF and one of its compounds of the acetone extract of the (HT) epicarp were investigated in this study using 40 adult male rats. Results: Phytochemical investigation of active WF revealed the presence of ten different flavonoids, among which two new natural compounds luteolin 7-O-[6″-O-α-L-rhamnopyranosyl]-β-D-galactopyranoside 3 and chrysoeriol 7-O-β-D-galactopyranosyl (1®2)-α-L-arabinofuranoside 5 were isolated. Supplementation of the WF improved glucose and insulin tolerance and significantly lowered blood glycosylated hemoglobin levels. On the other hand, compound 5 significantly reduced AST and ALT levels of liver, respectively. Likewise, the kidney functions were improved for both WF and compound 5 , whereby both urea and creatinine levels in serum were highly significant. Conclusion: The results justify the use of WF and compound 5 of the (HT) epicarp as anti-diabetic agent, taking into consideration that the contents of WF were mainly flavonoids.

%B Pharmacognosy Research %V 5 %P 22-29 %8 January 2013 %G eng %N 1 %9 Original Article %& 22 %R 10.4103/0974-8490.105644